Clinical Study

Ca030-001- A Phase 1/2 First-In-Human Study Of Bms-986249 Alone And In Combination With Nivolumab

Posted Date: Feb 26, 2020

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The main goal of this study is to characterize the safety, tolerability, and DLTs and to determine the MTD/RP2D of BMS-986249 administered as monotherapy and in combination with nivolumab in participants with advanced solid tumors.


To Be Eligible: Must Have Advanced Solid Tumor, Ecog 0-1, No Other Concurrent Active Malignancies Or Past Malignancies Within 2 Years, No Allergy To Study Treatments Or Components, No Uncontrolled Cardio Disease Or Active Infection


Phase 1, Advanced

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.